Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20053566 | 0.78 | ALDH1A1 (0.45) | ALDH1A1HPGDKDM4ELMNAHSD17B10 | |
| SCHEMBL1101522 | 0.64 | ALDH1A1 (0.77) | ALDH1A1HPGDKDM4ELMNAHSD17B10 | |
| SCHEMBL5968858 | 0.64 | ALDH1A1 (0.77) | ALDH1A1HPGDKDM4ELMNAHSD17B10 | |
| SCHEMBL751213 | 0.64 | ALDH1A1 (0.77) | ALDH1A1HPGDKDM4ELMNAHSD17B10 | |
| SCHEMBL3861132 | 0.64 | MAPT (0.41) | ALDH1A1HPGDLMNA | |
| SCHEMBL22240437 | 0.63 | ALOX5 (0.49) | ALDH1A1KDM4ELMNANPC1GAA | |
| SCHEMBL20440467 | 0.62 | HSD17B10 (0.59) | ALDH1A1HPGDKDM4ELMNAHSD17B10 | |
| SCHEMBL18470834 | 0.62 | HSD17B10 (0.59) | ALDH1A1HPGDKDM4ELMNAHSD17B10 | |
| SCHEMBL25336459 | 0.62 | MMP9 (0.66) | ALDH1A1HPGDKDM4ELMNAHSD17B10 | |
| SCHEMBL18415463 | 0.62 | MMP9 (0.66) | ALDH1A1HPGDKDM4ELMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174511-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174511-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | ALDH1A1 3781/4885HPGD 3961/4885KDM4E 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.